Banco Bilbao Vizcaya Argentaria S.A. Acquires 2,514 Shares of AbbVie Inc. $ABBV

Banco Bilbao Vizcaya Argentaria S.A. boosted its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 0.7% in the second quarter, Holdings Channel.com reports. The fund owned 378,917 shares of the company’s stock after acquiring an additional 2,514 shares during the quarter. AbbVie comprises 0.6% of Banco Bilbao Vizcaya Argentaria S.A.’s portfolio, making the stock its 26th biggest holding. Banco Bilbao Vizcaya Argentaria S.A.’s holdings in AbbVie were worth $70,309,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. FF Advisors LLC grew its holdings in shares of AbbVie by 3.6% in the second quarter. FF Advisors LLC now owns 1,539 shares of the company’s stock worth $286,000 after purchasing an additional 53 shares during the last quarter. Private Management Group Inc. boosted its position in AbbVie by 1.9% in the 1st quarter. Private Management Group Inc. now owns 2,938 shares of the company’s stock valued at $616,000 after buying an additional 54 shares during the period. LifeSteps Financial Inc. grew its stake in AbbVie by 0.7% in the 2nd quarter. LifeSteps Financial Inc. now owns 7,358 shares of the company’s stock worth $1,366,000 after acquiring an additional 54 shares in the last quarter. Silicon Valley Capital Partners grew its stake in AbbVie by 10.8% in the 1st quarter. Silicon Valley Capital Partners now owns 573 shares of the company’s stock worth $118,000 after acquiring an additional 56 shares in the last quarter. Finally, Seneca House Advisors increased its position in shares of AbbVie by 2.7% during the second quarter. Seneca House Advisors now owns 2,093 shares of the company’s stock worth $388,000 after acquiring an additional 56 shares during the period. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Stock Performance

Shares of AbbVie stock opened at $232.25 on Friday. The company has a market capitalization of $410.47 billion, a PE ratio of 110.60, a P/E/G ratio of 1.42 and a beta of 0.50. The company has a 50-day simple moving average of $224.49 and a two-hundred day simple moving average of $203.63. AbbVie Inc. has a one year low of $163.81 and a one year high of $244.81. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.61 and a current ratio of 0.74.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. The firm had revenue of $15.78 billion for the quarter, compared to the consensus estimate of $15.58 billion. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The company’s quarterly revenue was up 9.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Research analysts expect that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be issued a dividend of $1.73 per share. The ex-dividend date is Friday, January 16th. This represents a $6.92 annualized dividend and a dividend yield of 3.0%. This is a boost from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s dividend payout ratio (DPR) is currently 524.24%.

Analyst Ratings Changes

Several research analysts recently issued reports on the company. HSBC set a $225.00 price objective on AbbVie in a research note on Thursday, October 2nd. Raymond James Financial set a $256.00 price target on AbbVie in a research report on Monday, November 3rd. Berenberg Bank upgraded AbbVie from a “hold” rating to a “buy” rating and raised their price target for the company from $170.00 to $270.00 in a research note on Wednesday, September 17th. Bank of America raised their target price on shares of AbbVie from $220.00 to $251.00 and gave the company a “neutral” rating in a research report on Friday, October 3rd. Finally, Wells Fargo & Company upped their price target on shares of AbbVie from $240.00 to $260.00 and gave the stock an “overweight” rating in a research report on Friday, September 12th. Two analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and ten have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $238.55.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.